摘要
目的评价唑来磷酸联合化疗治疗非小细胞肺癌骨转移的疗效及不良反应。方法将48例非小细胞癌骨转移患者随机分为治疗组和对照组,每组24例,治疗组给予唑来磷酸同步化疗治疗,对照组单用唑来磷酸。结果治疗组和对照组的止痛总有效率分别为79.2%、54.2%,治疗组效果明显优于对照组,差异有统计学意义(P<0.05)。结论唑来磷酸联合化疗治疗非小细胞肺癌骨转移有较好疗效,值得临床推广应用。
Objective To evaluate the clinical efficacy and adverse reactions of zoledronic acid combined with chemotherapy in the treatment of patients with bone metastases of advanced non-small cell lung cancer （NSCLC）. Methods Forty eight cases of patients with NSCLC bone metastatis were randomly divided into two groups. 24 patients in treatment group received zoledronic acid combined with chemotherapy,24 patients in control group only received zoledronic acid.Results The total effective rate in pain relieving was 79.2% in treatment group and 54.2% in control group. The effect of the treatment group was better than that of the control group,which had statistical significance （ P 0.05）.Conclusion The effect of NSCLC bone metastatis treated with zoledronie acid injection is obvious.The drug is easy to be used in the clinical.
出处
《中国当代医药》
2013年第18期73-74,共2页
China Modern Medicine
关键词
唑来磷酸
非小细胞肺癌
骨转移
Zoledronic acid
Non-small cell lung cancer
Osseous metastasis
